Skip to main content
The BMJ logoLink to The BMJ
editorial
. 1996 May 11;312(7040):1177–1178. doi: 10.1136/bmj.312.7040.1177

The legacy of Edward Jenner.

M M Levine
PMCID: PMC2350929  PMID: 8634551

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clemens J. D., Ferreccio C., Levine M. M., Horwitz I., Rao M. R., Edwards K. M., Fritzell B. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA. 1992 Feb 5;267(5):673–678. [PubMed] [Google Scholar]
  2. Gustafsson L., Hallander H. O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996 Feb 8;334(6):349–355. doi: 10.1056/NEJM199602083340602. [DOI] [PubMed] [Google Scholar]
  3. Herrington D. A., Clyde D. F., Losonsky G., Cortesia M., Murphy J. R., Davis J., Baqar S., Felix A. M., Heimer E. P., Gillessen D. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987 Jul 16;328(6127):257–259. doi: 10.1038/328257a0. [DOI] [PubMed] [Google Scholar]
  4. Kotloff K. L., Nataro J. P., Losonsky G. A., Wasserman S. S., Hale T. L., Taylor D. N., Sadoff J. C., Levine M. M. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 1995 Nov;13(16):1488–1494. doi: 10.1016/0264-410x(95)00102-7. [DOI] [PubMed] [Google Scholar]
  5. Levine M. M., Ferreccio C., Black R. E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–1052. doi: 10.1016/s0140-6736(87)90480-6. [DOI] [PubMed] [Google Scholar]
  6. Orenstein W. A., Bernier R. H., Hinman A. R. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212–241. doi: 10.1093/oxfordjournals.epirev.a036023. [DOI] [PubMed] [Google Scholar]
  7. Rennels M. B., Glass R. I., Dennehy P. H., Bernstein D. I., Pichichero M. E., Zito E. T., Mack M. E., Davidson B. L., Kapikian A. Z. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics. 1996 Jan;97(1):7–13. [PubMed] [Google Scholar]
  8. Simanjuntak C. H., O'Hanley P., Punjabi N. H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A. R. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993 Nov;168(5):1169–1176. doi: 10.1093/infdis/168.5.1169. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES